FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362604457> ?p ?o ?g. }

• W4362604457 abstract "Abstract Background Genomic alterations, including loss of function in chromosome band 11q22-23, are frequently observed in neuroblastoma, which is the most common extracranial childhood tumour. In neuroblastoma, ATM , a DNA damage response-associated gene located on 11q22-23, has been linked to tumorigenicity. Genetic changes in ATM are heterozygous in most tumours. However, it is unclear how ATM is associated with tumorigenesis and cancer aggressiveness. Methods To elucidate its molecular mechanism of action, we established ATM -inactivated NGP and CHP-134 neuroblastoma cell lines using CRISPR/Cas9 genome editing. The knock out cells were rigorously characterized by analyzing proliferation, colony forming abilities and responses to PARP inhibitor (Olaparib). Western blot analyses were performed to detect different protein expression related to DNA repair pathway. ShRNA lentiviral vectors were used to knockdown ATM expression in SK-N-AS and SK-N-SH neuroblastoma cell lines. ATM knock out cells were stably transfected with FANCD2 expression plasmid to over-expressed the FANCD2. Moreover, knock out cells were treated with proteasome inhibitor MG132 to determine the protein stability of FANCD2. FANCD2, RAD51 and γH2AX protein expressions were determined by Immunofluorescence microscopy. Results Haploinsufficient ATM resulted in increased proliferation ( p < 0.01) and cell survival following PARP inhibitor (olaparib) treatment. However, complete ATM knockout decreased proliferation ( p < 0.01) and promoted cell susceptibility to olaparib ( p < 0.01). Complete loss of ATM suppressed the expression of DNA repair-associated molecules FANCD2 and RAD51 and induced DNA damage in neuroblastoma cells. A marked downregulation of FANCD2 expression was also observed in shRNA-mediated ATM-knockdown neuroblastoma cells. Inhibitor experiments demonstrated that the degradation of FANCD2 was regulated at the protein level through the ubiquitin–proteasome pathway. Reintroduction of FANCD2 expression is sufficient to reverse decreased proliferation mediated by ATM depletion. Conclusions Our study revealed the molecular mechanism underlying ATM heterozygosity in neuroblastomas and elucidated that ATM inactivation enhances the susceptibility of neuroblastoma cells to olaparib treatment. These findings might be useful in the treatment of high-risk NB patients showing ATM zygosity and aggressive cancer progression in future." @default.
• W4362604457 created "2023-04-06" @default.
• W4362604457 creator A5005617601 @default.
• W4362604457 creator A5010569178 @default.
• W4362604457 creator A5012281840 @default.
• W4362604457 creator A5012468551 @default.
• W4362604457 creator A5024295857 @default.
• W4362604457 creator A5024828264 @default.
• W4362604457 creator A5049696172 @default.
• W4362604457 creator A5051152724 @default.
• W4362604457 creator A5064427269 @default.
• W4362604457 creator A5065766425 @default.
• W4362604457 creator A5082871121 @default.
• W4362604457 creator A5091595230 @default.
• W4362604457 date "2023-04-05" @default.
• W4362604457 modified "2023-10-17" @default.
• W4362604457 title "ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors" @default.
• W4362604457 cites W1547168939 @default.
• W4362604457 cites W1592248506 @default.
• W4362604457 cites W1965864793 @default.
• W4362604457 cites W1971646622 @default.
• W4362604457 cites W1973771504 @default.
• W4362604457 cites W1981086877 @default.
• W4362604457 cites W1987798097 @default.
• W4362604457 cites W2009007206 @default.
• W4362604457 cites W2012040948 @default.
• W4362604457 cites W2017297714 @default.
• W4362604457 cites W2019225967 @default.
• W4362604457 cites W2029304297 @default.
• W4362604457 cites W2042619042 @default.
• W4362604457 cites W2044209989 @default.
• W4362604457 cites W2049921243 @default.
• W4362604457 cites W2067606868 @default.
• W4362604457 cites W2071457560 @default.
• W4362604457 cites W2088327962 @default.
• W4362604457 cites W2096193191 @default.
• W4362604457 cites W2096815117 @default.
• W4362604457 cites W2097963861 @default.
• W4362604457 cites W2110938265 @default.
• W4362604457 cites W2111772438 @default.
• W4362604457 cites W2114031931 @default.
• W4362604457 cites W2119346494 @default.
• W4362604457 cites W2148798204 @default.
• W4362604457 cites W2151952239 @default.
• W4362604457 cites W2166852863 @default.
• W4362604457 cites W2326401583 @default.
• W4362604457 cites W2408982653 @default.
• W4362604457 cites W2434741649 @default.
• W4362604457 cites W2465330019 @default.
• W4362604457 cites W2490467724 @default.
• W4362604457 cites W2626253438 @default.
• W4362604457 cites W2747877968 @default.
• W4362604457 cites W2750605024 @default.
• W4362604457 cites W2774372894 @default.
• W4362604457 cites W2952634370 @default.
• W4362604457 cites W2975056146 @default.
• W4362604457 cites W3006850701 @default.
• W4362604457 cites W3007802993 @default.
• W4362604457 cites W3014262941 @default.
• W4362604457 cites W3014298915 @default.
• W4362604457 cites W3081569548 @default.
• W4362604457 cites W3103778988 @default.
• W4362604457 cites W3186303608 @default.
• W4362604457 cites W3193542749 @default.
• W4362604457 cites W3214096503 @default.
• W4362604457 cites W3215759223 @default.
• W4362604457 cites W4249845735 @default.
• W4362604457 doi "https://doi.org/10.1186/s12885-023-10772-y" @default.
• W4362604457 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37020276" @default.
• W4362604457 hasPublicationYear "2023" @default.
• W4362604457 type Work @default.
• W4362604457 citedByCount "1" @default.
• W4362604457 countsByYear W43626044572023 @default.
• W4362604457 crossrefType "journal-article" @default.
• W4362604457 hasAuthorship W4362604457A5005617601 @default.
• W4362604457 hasAuthorship W4362604457A5010569178 @default.
• W4362604457 hasAuthorship W4362604457A5012281840 @default.
• W4362604457 hasAuthorship W4362604457A5012468551 @default.
• W4362604457 hasAuthorship W4362604457A5024295857 @default.
• W4362604457 hasAuthorship W4362604457A5024828264 @default.
• W4362604457 hasAuthorship W4362604457A5049696172 @default.
• W4362604457 hasAuthorship W4362604457A5051152724 @default.
• W4362604457 hasAuthorship W4362604457A5064427269 @default.
• W4362604457 hasAuthorship W4362604457A5065766425 @default.
• W4362604457 hasAuthorship W4362604457A5082871121 @default.
• W4362604457 hasAuthorship W4362604457A5091595230 @default.
• W4362604457 hasBestOaLocation W43626044571 @default.
• W4362604457 hasConcept C121608353 @default.
• W4362604457 hasConcept C134935766 @default.
• W4362604457 hasConcept C143425029 @default.
• W4362604457 hasConcept C153911025 @default.
• W4362604457 hasConcept C173396325 @default.
• W4362604457 hasConcept C182979987 @default.
• W4362604457 hasConcept C190232843 @default.
• W4362604457 hasConcept C2776715637 @default.
• W4362604457 hasConcept C2778367456 @default.
• W4362604457 hasConcept C2778480876 @default.
• W4362604457 hasConcept C2778506107 @default.
• W4362604457 hasConcept C2779962180 @default.
• W4362604457 hasConcept C2781312401 @default.

• next